Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance
Portfolio Pulse from
Heron Therapeutics reported positive YTD 2024 Adjusted EBITDA of $1.4 million and expects Q4 2024 net revenue between $37 million and $43 million. The company announced the approval of ZYNRELEF's Vial Access Needle and its inclusion in CMS's Non-Opioid Policy for separate payment.
November 12, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Heron Therapeutics reported positive YTD 2024 Adjusted EBITDA and narrowed Q4 revenue guidance. ZYNRELEF's Vial Access Needle was approved and included in CMS's Non-Opioid Policy, potentially boosting future revenues.
The positive EBITDA and narrowed revenue guidance indicate financial stability and potential growth. The approval of ZYNRELEF's VAN and its inclusion in CMS's policy could lead to increased adoption and revenue, positively impacting HRTX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100